JP2013525286A - タンパク質チロシンキナーゼ活性の阻害剤 - Google Patents

タンパク質チロシンキナーゼ活性の阻害剤 Download PDF

Info

Publication number
JP2013525286A
JP2013525286A JP2013504076A JP2013504076A JP2013525286A JP 2013525286 A JP2013525286 A JP 2013525286A JP 2013504076 A JP2013504076 A JP 2013504076A JP 2013504076 A JP2013504076 A JP 2013504076A JP 2013525286 A JP2013525286 A JP 2013525286A
Authority
JP
Japan
Prior art keywords
alkyl
heterocyclyl
group
substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013504076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525286A5 (enExample
Inventor
ステファン・レペル
フランク・レペル
スティーブン・ウィリアム・クラリッジ
リジェ・ジャン
フレデリック・ゴーデット
マイケル・マニオン
範典 佐藤
洋平 結城
雅司 岸田
アルカディ・ヴェスブール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methylgene Inc
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of JP2013525286A publication Critical patent/JP2013525286A/ja
Publication of JP2013525286A5 publication Critical patent/JP2013525286A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013504076A 2010-04-16 2011-04-08 タンパク質チロシンキナーゼ活性の阻害剤 Ceased JP2013525286A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
US61/324,803 2010-04-16
PCT/CA2011/000394 WO2011127567A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity

Publications (2)

Publication Number Publication Date
JP2013525286A true JP2013525286A (ja) 2013-06-20
JP2013525286A5 JP2013525286A5 (enExample) 2014-05-15

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013504076A Ceased JP2013525286A (ja) 2010-04-16 2011-04-08 タンパク質チロシンキナーゼ活性の阻害剤
JP2013504075A Ceased JP2013523846A (ja) 2010-04-16 2011-04-08 タンパク質チロシンキナーゼ活性の阻害剤および眼部の障害を治療するためのそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013504075A Ceased JP2013523846A (ja) 2010-04-16 2011-04-08 タンパク質チロシンキナーゼ活性の阻害剤および眼部の障害を治療するためのそれらの使用

Country Status (19)

Country Link
US (3) US8455484B2 (enExample)
EP (2) EP2563794A4 (enExample)
JP (2) JP2013525286A (enExample)
KR (2) KR20130058006A (enExample)
CN (2) CN102947315A (enExample)
AR (2) AR080871A1 (enExample)
AU (2) AU2011241422B2 (enExample)
CA (2) CA2796008A1 (enExample)
CO (2) CO6630193A2 (enExample)
EA (2) EA201291055A1 (enExample)
MX (2) MX2012012032A (enExample)
MY (1) MY157319A (enExample)
NZ (2) NZ602954A (enExample)
PH (2) PH12012502070A1 (enExample)
SG (2) SG184883A1 (enExample)
TW (2) TW201204734A (enExample)
UA (1) UA108878C2 (enExample)
WO (2) WO2011127565A1 (enExample)
ZA (2) ZA201207482B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523846A (ja) * 2010-04-16 2013-06-17 メチルジーン・インコーポレイテッド タンパク質チロシンキナーゼ活性の阻害剤および眼部の障害を治療するためのそれらの使用
JP2017048131A (ja) * 2015-08-31 2017-03-09 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777776B (zh) * 2007-08-29 2021-06-08 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
UA100262C2 (uk) * 2008-03-05 2012-12-10 Метилген Інк. Інгібітори активності протеїнтирозинкінази
US20130090327A1 (en) * 2011-09-30 2013-04-11 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
US9085517B2 (en) 2011-12-15 2015-07-21 Pfizer Limited Sulfonamide derivatives
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016183150A1 (en) * 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504804A (ja) * 2005-05-20 2009-02-05 メチルジーン インコーポレイテッド Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
WO2009026717A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
CN101031570B (zh) * 2004-07-30 2012-09-05 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
NZ563774A (en) * 2005-05-20 2010-04-30 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
EP2563794A4 (en) * 2010-04-16 2013-12-04 Methylgene Inc INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY AND ITS USE FOR THE TREATMENT OF EYE DISEASES
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504804A (ja) * 2005-05-20 2009-02-05 メチルジーン インコーポレイテッド Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
WO2009026717A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523846A (ja) * 2010-04-16 2013-06-17 メチルジーン・インコーポレイテッド タンパク質チロシンキナーゼ活性の阻害剤および眼部の障害を治療するためのそれらの使用
JP2017048131A (ja) * 2015-08-31 2017-03-09 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法

Also Published As

Publication number Publication date
CA2796008A1 (en) 2011-10-20
NZ602948A (en) 2014-09-26
UA108878C2 (ru) 2015-06-25
ZA201207557B (en) 2013-06-26
TW201204735A (en) 2012-02-01
KR20130058006A (ko) 2013-06-03
AR080875A1 (es) 2012-05-16
CA2796054A1 (en) 2011-10-20
SG184883A1 (en) 2012-11-29
ZA201207482B (en) 2013-09-25
NZ602954A (en) 2014-11-28
EP2563794A4 (en) 2013-12-04
CN103025740B (zh) 2015-07-01
PH12012502073A1 (en) 2013-02-11
MX2012012032A (es) 2012-12-17
KR20130100234A (ko) 2013-09-10
AU2011241420B2 (en) 2015-04-16
EP2563795A4 (en) 2013-10-23
EA201291052A1 (ru) 2013-04-30
AU2011241422B2 (en) 2015-05-07
US8455484B2 (en) 2013-06-04
US20140315801A1 (en) 2014-10-23
US20110257100A1 (en) 2011-10-20
WO2011127565A1 (en) 2011-10-20
CO6640224A2 (es) 2013-03-22
US20110257175A1 (en) 2011-10-20
EP2563795A1 (en) 2013-03-06
MY157319A (en) 2016-05-31
TW201204734A (en) 2012-02-01
PH12012502070A1 (en) 2015-05-08
CN103025740A (zh) 2013-04-03
US8906852B2 (en) 2014-12-09
EP2563794A1 (en) 2013-03-06
AR080871A1 (es) 2012-05-16
MX2012012031A (es) 2012-12-17
AU2011241422A1 (en) 2012-11-01
WO2011127567A1 (en) 2011-10-20
SG184882A1 (en) 2012-11-29
EA201291055A1 (ru) 2013-09-30
CO6630193A2 (es) 2013-03-01
JP2013523846A (ja) 2013-06-17
CN102947315A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
JP2013525286A (ja) タンパク質チロシンキナーゼ活性の阻害剤
TWI571468B (zh) 蛋白質酪胺酸激酶活性抑制劑
JP5661485B2 (ja) タンパク質チロシンキナーゼ活性の阻害剤
ES2659045T3 (es) Derivados de oxopiridina sustituidos
US20130090327A1 (en) Inhibitors of Protein Tyrosine Kinase Activity
US20130096088A1 (en) Inhibitors of Protein Tyrosine Kinase Activity
WO2024149239A1 (zh) 杂芳环化合物及其制备方法和用途
HK1182379A (en) Inhibitors of protein tyrosine kinase activity
HK1139407B (en) Inhibitors of protein tyrosine kinase activity
HK1139407A (en) Inhibitors of protein tyrosine kinase activity
HK1155977A (en) Inhibitors of protein tyrosine kinase activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150520

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150915

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20160126